Company News

Dr Oliver Sartor is an internationally recognised medical oncologist and scientist specialising in prostate cancer and radiopharmaceutical therapies.

A study co-led by WEHI and the Peter Doherty Institute for Infection and Immunity has found that existing HIV drugs can suppress transmission of the HTLV-1 virus in mice.

Australian regenerative medicine company Osteopore (ASX:OSX) has secured clearance from the Research Governance Office at Princess Alexandra Hospital in Brisbane for its clinical trial for jawbone regeneration.

Australian allogeneic cellular medicines company Mesoblast (ASX:MSB) has reported gross revenue of US$13.2 million from the sales of Ryoncil following its launch at the end of March.

Australian-headquartered medical device company Atomo Diagnostics (ASX:AT1) has announced that it has placed the shortfall of $727,612.50 from the Share Purchase Plan with a range of sophisticated investors.

Brandon BioCatalyst has welcomed the inclusion of its national biotechnology incubator, CUREator, in a new $100 million program funded by the Australian Government's Medical Research Future Fund.

Viral Vector Manufacturing Facility and Cell Therapies have signed an MoU to explore strategic collaboration opportunities aimed at strengthening the onshore development and manufacture of Advanced Therapy Medicinal Products.

Health Minister Mark Butler has launched the Cancer Australia Research Initiative, a new program designed to address emerging needs in cancer research.

Australian clinical-stage biotechnology company Noxopharm (ASX:NOX) has announced the administration of the first SOF-SKN dose in the HERACLES trial.

Lumos Diagnostics (ASX:LDX) has signed an exclusive US distribution and supply agreement for FebriDx, valued at up to US$317 million (approximately AUD$487 million), with PHASE Scientific International.

Imugene (ASX:IMU) has announced it has received firm commitments from institutional and sophisticated investors for a $22.5 million placement and is launching a share purchase plan for existing eligible shareholders to raise up to $15 million.

Scientists from the Centenary Institute and the University of Sydney have made a discovery that could lead to safer and more effective gene therapies for a range of serious genetic disorders, including Duchenne muscular dystrophy, Pompe disease and haemophilia.